Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AT-7687
Therapeutic Area : Nutrition and Weight Loss
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Antag Receives FDA Clearance For IND Application For AT-7687
Details : AT-7687 is a peptide GIP receptor antagonist designed for once-weekly subcutaneous, currently, it is being evaluated in the treatment of obesity.
Brand Name : AT-7687
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 09, 2024
Lead Product(s) : AT-7687
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?